References

Plasma-based NGS has significantly advanced precision oncology by identifying genetic mutations and shaping countless life-changing targeted therapies—but genomics is only a narrow view of cancer.²

FOR BIOPHARMA PARTNERS

Epigenetic changes have a tremendous impact on cancer formation and progression,
yet epigenomic biomarkers remain untapped.3,4

Harness the power of epigenomics with the Guardant Infinity platform.¹

Advance precision oncology into a new era.

NGS, next-generation sequencing.